


The WIN Consortium in Precision Oncology

www.winconsortium.org



WIN was formed on the premise that Consortium members can accomplish together what no single institution or group of patients can do alone.

WIN was founded in France as a non-profit by **Dr. John Mendelsohn**, Past President MD Anderson Cancer Center, Houston, Chairman of WIN until his death and **Prof. Thomas Tursz**, General Director Gustave Roussy, France.

BOLD MISSION Significantly improve survival of cancer patients across the world through international collaboration.

STRATEGY: Perform proof-of-concept cancer clinical trials designed to explore novel strategies and tools to increase efficacy of Precision Oncology and improve early diagnosis

Publications

WINTHER trial results

J. Rodon et al., Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. *Nature Medicine* volume 25, pages 751-758 (2019)

Simplified interventional mapping system (SIMS)

Lazar V, et al. Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors. *Therapeutic Advances in Medical Oncology*. 2024;16

Solomon B, et al. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. *Cancer Med*. (2022) ;00:1-11

Digital Display Precision Predictor (DDPP)

Lazar, V., et al., Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. (2021) *npj Precis. Onc.* 5, 33.

Lazar, V., et al., Transcriptomics in tumor and normal lung tissues identify patients with early stage NSCLC with high risk of post-surgery recurrence who may benefit from adjuvant therapies *JCO Precision Oncology* no. 6 (2022) e2200072. Published online

Lazar, V., et al., Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung. *Therapeutic Advances in Medical Oncology* (2022), Vol. 14: 1-15

Lazar, V., et al., A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology. *Ther Adv Med Oncol* (2023), Vol. 15: 1-15

WIN History

John Mendelsohn, Past President MD Anderson Cancer Center, Houston, USA

Chair, WIN 2010 - 2018



Thomas Tursz, Past General Director Gustave Roussy, Villejuif, France

Vice-Chair, WIN 2010 - 2012, 2016 - 2018



Alexander Eggermont, Past General Director Gustave Roussy, Villejuif, France

Vice-Chair, WIN 2012 - 2016



Josep Tabernero, Head Vall d'Hebron Institute of Oncology, Barcelona, Spain

Vice-Chair, WIN 2018 - 2023



Richard L. Schilsky, Past President, former Executive VP and Chief Medical Officer, ASCO, USA

Chair, WIN 2018 - 2023



Wafik El-Deiry, Director, Legorreta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, USA

Chair, WIN 2024 -



WIN Executive Committee



Prof. Wafik S. El-Deiry
Chair, WIN Consortium
Director, Legorreta Cancer
Center, Brown University (USA)



Dr. Richard L. Schilsky
Chair Emeritus, WIN Consortium
Professor Emeritus, University of
Chicago
Past President & Chief Medical
Officer, American Society of Clinical
Oncology (ASCO) (USA)



Dr. Razelle Kurzrock
Chief Medical Officer, WIN Consortium
Prof. of Medicine, Associate Director,
Clinical Research, MCW Cancer Center
and Linda T. & John A. Mellowes
Chair of Precision Oncology (USA)



Prof. Apostolia M. Tsimberidou
Vice-Chair, WIN Consortium
Professor of Medicine in the
Department of Investigational Cancer
Therapeutics and a Katherine Russell
Dixie Distinguished Endowed
Professor at The University of Texas,
MD Anderson Cancer Center (USA)



Dr. Sewanti Limaye
Vice-Chair, WIN Consortium
Director Medical & Precision
Oncology, Director Clinical and
Translational Oncology Research,
Sir HN Reliance Foundation
Hospital and Research Centre
(India)



Prof. Marina Sekacheva
Chair, Membership Committee,
WIN Consortium
Director of Institute for
Personalized Oncology, I.M
Sechenov First Medical State
University,
(Russian Federation)



Dr. Jacques Raynaud,
Senior Advisor, WIN
Consortium



Catherine Bresson
Director, Operational
Team, WIN Consortium

WIN 34 Members across the Globe

Academic Institutions in Americas



Academic Institutions in Asia-Pacific



Academic Institutions in Europe



Small & Medium Enterprises




Non-Profit Organizations



World-class academic medical centers (26), SME (3), research and patient advocate organizations (5).

34 members in 18 countries and 5 continents
Access to > 5,000,000 patients
www.winconsortium.org



#	Institution	#	Institution	#	Institution
1	SWOG Cancer Research Network, USA	13	INCLIVA, Spain	25	King Hussein Cancer Center, Jordan
2	Avera Cancer Institute, USA	14	Vall d'Hebron Institute of Oncology (VHIO), Spain	26	I.M. Sechenov First Moscow State Medical University, Russia
3	American Cancer Society, USA	15	Catalan Institute of Oncology (ICO), Spain	27	National Center for Cancer Care & Research Hamad Medical Corporation, Qatar
4	Atrium Health Wake Forest Baptist Comprehensive Cancer Center, USA	16	Cure 51, France	28	Burjeel Medical City, UAE
5	Rutgers Cancer Institute, USA	17	Centre Leon Berard, France	29	Tata Memorial Centre, India
6	Cancer is An A' LLC, USA	18	Luxembourg Institute of Health, Luxembourg	30	Sir H.N. Reliance Foundation Hospital and Research Centre, India
7	Chaim Medical Research Organization, USA	19	Centre Hospitalier de Luxembourg, Luxembourg	31	Vyes Cancer Research Pvt (VCR Park), India
8	Segal Cancer Centre, Jewish General Hospital, McGill University, Canada	20	Novocure, Switzerland	32	Fudan University Shanghai Cancer Center, China
9	Legorreta Cancer Center at Brown University, USA	21	The University of Medicine and Pharmacy Iuliu Hatieganu, Romania	33	Institute of Science Tokyo Hospital, Japan
10	TargetCancer Foundation, USA	22	Medicana Health Group, Demiray Precision Oncology Center, Turkey	34	The Kinghorn Cancer Centre, Australia
11	The Jackson Laboratory, USA	23	Ben-Gurion University of the Negev, Israel		
12	Barretos Cancer Hospital, Brazil	24	Sheba Medical Center, Israel		


WIN Value Proposition

- ❑ Access to:
 - Global thought leaders in Precision Oncology
 - Platform of leading cancer centers across the world → rapid accrual/diversity of population
- ❑ Expertise in genomics and transcriptomics
- ❑ Experience and success with:
 - Complex biomarker-directed clinical trials (WINTHER trial)
 - Obtaining high quality tissues and bloods for comprehensive omics
 - Managing international multi-site trials
 - International Molecular Tumor Board
- ❑ Ability to partner with companies and philanthropic organizations or individuals to perform Precision Oncology studies to:
 - Better identify treatment options for patients including optimal dosing of novel combination therapies
 - Understand mechanisms of resistance to cancer therapy
 - Improve patients' treatment follow-up and early diagnosis non-invasively
 - Accelerate drug development through better patient selection

Lazar V, et al. Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors. *Therapeutic Advances in Medical Oncology*. 2024;16

El-Deiry, et al., Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing Next-Generation Precision Oncology to Patients. *Oncotarget*. 2025; 16:140-162

A Hernando-Calvo, et al., Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment *Oncotarget*. 2025; 16:456-466.
O. Landau, et al. OncoAID: An Open Access Targeted Anti-Cancer Database Front. Pharmacol., 13 August 2025 Sec. Pharmacology of Anti-Cancer Drugs Volume 16 - 2025



14th WIN Symposium, held in cooperation with APM on October 3-4, 2025, in Philadelphia, USA, and co-chaired by Prof. W. El-Deiry and Dr. R. Kurzrock, marked another highlight in a remarkable series of symposia. The conference featured a special session with Nobel Laureate Dr. William G. Kaelin Jr. (Harvard Medical School, Dana-Farber Cancer Institute).

WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East

A Vision for WIN's Future

- ☐ Expand the WIN membership with additional:
 - World-class cancer centers in US and across the globe
 - Diagnostics, AI, pharma companies, patient-advocacy organizations, non-profits
- ☐ Leveraging WIN's platform for global academic members to:
 - Partner with companies for compelling Precision Oncology and Early Diagnosis studies across the globe
 - Build upon transcriptomics' experience acquired in international clinical trials like WINTHER and others that have so much potential → incorporating Functional Precision Medicine assays and novel modalities
 - Accelerate trial results delivery and simplify management of multi-site international trials
- ☐ Leverage WIN IP (algorithm for patient's treatment matching and patient stratification)
- ☐ New initiatives such as international Molecular Tumor Board and International Precision Oncology Fellowship
- ☐ Involve WIN's exceptional SAB - Innovation and Collaboration globally to ensure continued success
- ☐ Strengthen relationships with professional societies (ACS, ASCO, AACI, AACR, etc.)

Membership Benefits

- ☐ Representation at international General Assembly (right to vote on all decisions)
- ☐ Access to governance positions (2-year mandates)
- ☐ Ability to participate in WIN Committees and International Molecular Tumor Board for faculty
- ☐ Ability to participate in WIN-managed studies
- ☐ Ability to propose studies to be performed in WIN member institutions, but no obligation
- ☐ Each project is subject to contract negotiated in good faith. Usual IP rules apply
- ☐ Each project needs a separate funding mechanism. All participants in studies required to participate in the effort
- ☐ Visibility on website, symposia


Annual Membership Dues

Academics: From 5,000 to 50,000 € depending on research budget

Industries: Pharma 250,000 € ; Technology partners 100,000 €

Committees

- ❑ International Molecular Tumor Board with Precision Oncology experts from 18 sites and 13 countries. Discussing complex clinical cases with a focus on tailored combinations. Cases are being published.



#	Institution	#	Institution
1	Avera Cancer Institute, USA	10	Centre Léon Berard, France
2	Rutgers Cancer Institute, USA	11	Centre Hospitalier de Luxembourg, Luxembourg
3	Chaim Medical Resource Organization, USA	12	Sheba Medical Center, Israel
4	Segal Cancer Centre, Jewish General Hospital, McGill University, Canada	13	King Hussein Cancer Center, Jordan
5	Legorreta Cancer Center at Brown University, USA	14	Burjeel Medical City, UAE
6	The Jackson Laboratory, USA	15	Sir H.N. Reliance Foundation Hospital and Research Centre, India
7	Vall d'Hebron Institute of Oncology (VHIO), Spain	16	Fudan University Shanghai Cancer Center, China
8	Catalan Institute of Oncology (ICO), Spain	17	Institute of Science Tokyo Hospital, Japan
9	Worldwide Innovative Network (WIN) Association - WIN Consortium, France	18	The Kinghorn Cancer Centre, Australia

- ❑ Membership Committee
- ❑ Symposium Committee
- ❑ Training and Publication Committee
- ❑ Data Science Committee
- ❑ Rare cancers Committee
- ❑ Disease Committees: GI, GU, Thoracic, CNS, Gynaecology, Breast
- ❑ Biomarkers Committee
- ❑ Precision Radiation Oncology / Imaging Committee
- ❑ Novel Agents Committee
- ❑ Regulatory Issues in Precision Oncology Committee
- ❑ Novel tissue agnostic biomarkers Committee
- ❑ Living Guidelines Committee
- ❑ Pediatrics Committee